Literature DB >> 1345772

Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium.

R M Bigsby1, A X Li, J Bomalaski, F B Stehman, K Y Look, G P Sutton.   

Abstract

HER-2/neu oncogene protein, epidermal growth factor receptor, progesterone receptor, and estrogen receptor were examined immunohistochemically in specimens of normal and neoplastic endometrium. Tissues obtained at the time of hysterectomy were snap-frozen at liquid nitrogen temperature and serially sectioned at 4 microns. Normal endometrial epithelial cells stained with anti-epidermal growth factor receptor and anti-HER-2/neu with intensities graded from 0 to 3+. Of the 49 endometrial malignancies studied, seven (14%) contained tissue exhibiting HER-2/neu staining in excess (4+) of any of the normal tissues or the other 42 cancer specimens. Expression of both HER-2/neu and steroid receptors was heterogeneous within these seven tumors. To examine this heterogeneity more closely, sections of these and other tumors were double-stained for HER-2/neu and progesterone receptor. It was found that the cells exhibiting 4+ HER-2/neu staining were progesterone receptor-negative. Conversely, cells that were progesterone receptor-positive within the same specimen exhibited HER-2/neu immunostaining equal to or less than 3+. All specimens containing 4+ HER-2/neu tissue were graded 1 or 2 adenocarcinomas, stage I. Thus, there is an inverse relationship between overexpression of HER-2/neu and progesterone receptor in endometrial cancer. On the other hand, overexpression of HER-2/neu in endometrial cancer does not seem to be related to loss of other differentiated characteristics. The prognostic value of these observations awaits continued study.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1345772

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  6 in total

Review 1.  Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.

Authors:  Henry D Reyes; Kristina W Thiel; Matthew J Carlson; Xiangbing Meng; Shujie Yang; Jean-Marie Stephan; Kimberly K Leslie
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

2.  Endometrial carcinoma: immunohistochemically detected proliferation index is a prognosticator of long-term outcome.

Authors:  A M Gassel; J Backe; S Krebs; S Schön; H Caffier; H K Müller-Hermelink
Journal:  J Clin Pathol       Date:  1998-01       Impact factor: 3.411

Review 3.  Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know.

Authors:  Joyce Liu; Shannon N Westin
Journal:  Gynecol Oncol       Date:  2016-04       Impact factor: 5.482

Review 4.  Personalized therapy in endometrial cancer: challenges and opportunities.

Authors:  Shannon N Westin; Russell R Broaddus
Journal:  Cancer Biol Ther       Date:  2012-01-01       Impact factor: 4.742

5.  Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.

Authors:  G E Konecny; N Venkatesan; G Yang; J Dering; C Ginther; R Finn; M Rahmeh; M Schoenberg Fejzo; D Toft; S-W Jiang; D J Slamon; K C Podratz
Journal:  Br J Cancer       Date:  2008-03-11       Impact factor: 7.640

6.  The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas.

Authors:  Aylin Ege Gul; Sevinc Hallac Keser; Nagehan Ozdemir Barisik; Nilufer Onak Kandemir; Caglar Cakir; Sibel Sensu; Nimet Karadayi
Journal:  Diagn Pathol       Date:  2010-02-18       Impact factor: 2.644

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.